Table of Contents Author Guidelines Submit a Manuscript
Journal of Immunology Research
Volume 2017 (2017), Article ID 5619402, 7 pages
https://doi.org/10.1155/2017/5619402
Review Article

Clinical Relevance of HLA Antibodies in Kidney Transplantation: Recent Data from the Heidelberg Transplant Center and the Collaborative Transplant Study

1Transplantation Immunology, Institute of Immunology, University of Heidelberg, Heidelberg, Germany
2Department of Pediatrics I, University Children’s Hospital, University of Heidelberg, Heidelberg, Germany
3Department of Transplantation and General Surgery, University of Heidelberg, Heidelberg, Germany
4Division of Nephrology, University of Heidelberg, Heidelberg, Germany

Correspondence should be addressed to Caner Süsal

Received 23 December 2016; Revised 2 March 2017; Accepted 8 March 2017; Published 4 June 2017

Academic Editor: Senthami R. Selvan

Copyright © 2017 Caner Süsal et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. H. G. Otten, M. C. Verhaar, H. P. Borst, R. J. Hené, and A. D. van Zuilen, “Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure,” American Journal of Transplantation, vol. 12, no. 6, pp. 1618–1623, 2012. View at Publisher · View at Google Scholar · View at Scopus
  2. A. Loupy, C. Lefaucheur, D. Vernerey et al., “Complement-binding anti-HLA antibodies and kidney-allograft survival,” The New England Journal of Medicine, vol. 369, no. 13, pp. 1215–1226, 2013. View at Publisher · View at Google Scholar · View at Scopus
  3. S. M. Schaefer, C. Süsal, G. Opelz et al., “Pre-transplant soluble CD30 in combination with total DSA but not pre-transplant C1q-DSA predicts antibody-mediated graft loss in presensitized high-risk kidney transplant recipients,” HLA, vol. 87, no. 2, pp. 89–99, 2016. View at Publisher · View at Google Scholar
  4. C. Süsal, D. Wettstein, B. Döhler et al., “Association of kidney graft loss with de novo produced donor-specific and non-donor-specific HLA antibodies detected by single antigen testing,” Transplantation, vol. 99, no. 9, pp. 1976–1980, 2015. View at Publisher · View at Google Scholar · View at Scopus
  5. C. Morath, J. Beimler, G. Opelz et al., “An integrative approach for the transplantation of high-risk sensitized patients,” Transplantation, vol. 90, no. 6, pp. 645–653, 2010. View at Publisher · View at Google Scholar · View at Scopus
  6. C. Süsal and C. Morath, “Current approaches to the management of highly sensitized kidney transplant patients,” Tissue Antigens, vol. 77, no. 3, pp. 177–186, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. C. Süsal, B. Döhler, A. Ruhenstroth et al., “Donor-specific antibodies require preactivated immune system to harm renal transplant,” EBioMedicine, vol. 9, no. 7, pp. 366–371, 2016. View at Publisher · View at Google Scholar · View at Scopus
  8. C. Süsal and G. Opelz, “Kidney graft failure and presensitization against HLA class I and class II antigens,” Transplantation, vol. 73, no. 8, pp. 1269–1273, 2002. View at Publisher · View at Google Scholar
  9. C. Süsal, B. Döhler, and G. Opelz, “Presensitized kidney graft recipients with HLA class I and II antibodies are at increased risk for graft failure: a Collaborative Transplant Study report,” Human Immunology, vol. 70, no. 8, pp. 569–573, 2009. View at Publisher · View at Google Scholar · View at Scopus
  10. F. H. Claas, A. Rahmel, and I. I. Doxiadis, “Enhanced kidney allocation to highly sensitized patients by the acceptable mismatch program,” Transplantation, vol. 88, no. 4, pp. 447–452, 2009. View at Publisher · View at Google Scholar · View at Scopus
  11. N. Kohei, T. Hirai, K. Omoto, H. Ishida, and K. Tanabe, “Chronic antibody-mediated rejection is reduced by targeting B-cell immunity during an introductory period,” American Journal of Transplantation, vol. 12, no. 2, pp. 469–476, 2012. View at Publisher · View at Google Scholar · View at Scopus
  12. C. Süsal, B. Döhler, M. Sadeghi, J. Ovens, and G. Opelz, “HLA antibodies and the occurrence of early adverse events in the modern era of transplantation: a collaborative transplant study report,” Transplantation, vol. 87, no. 9, pp. 1367–1371, 2009. View at Publisher · View at Google Scholar · View at Scopus
  13. “CTS Newsletter 2,” 2015, December 2016, http://www.ctstransplant.org/public/newsletters/2015.
  14. A. Fichtner, C. Süsal, B. Höcker et al., “Association of C1q-fixing DSA with late graft failure in pediatric renal transplant recipients,” Pediatric Nephrology, vol. 31, no. 7, pp. 1157–1166, 2016. View at Publisher · View at Google Scholar · View at Scopus
  15. C. Süsal, S. Pelzl, B. Döhler, and G. Opelz, “Identification of highly responsive kidney transplant recipients using pretransplant soluble CD30,” Journal of the American Society of Nephrology, vol. 13, no. 6, pp. 1650–1656, 2002. View at Google Scholar
  16. L. M. Rodríguez, S. C. París, M. Arbeláez et al., “Kidney graft recipients with pretransplantation HLA class I antibodies and high soluble CD30 are at high risk for graft loss,” Human Immunology, vol. 68, no. 8, pp. 652–660, 2007. View at Publisher · View at Google Scholar · View at Scopus
  17. L. L. Langan, L. P. Park, T. L. Hughes et al., “Post-transplant HLA class II antibodies and high soluble CD30 levels are independently associated with poor kidney graft survival,” American Journal of Transplantation, vol. 7, no. 4, pp. 847–856, 2007. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Süsal, B. Döhler, M. Sadeghi et al., “Posttransplant sCD30 as a predictor of kidney graft outcome,” Transplantation, vol. 91, no. 12, pp. 1364–1369, 2011. View at Publisher · View at Google Scholar · View at Scopus
  19. P. C. Grenzi, É. F. Campos, H. Tedesco-Silva et al., “Association of high post-transplant soluble CD30 serum levels with chronic allograft nephropathy,” Transplant Immunology, vol. 29, no. 1–4, pp. 34–38, 2013. View at Publisher · View at Google Scholar · View at Scopus
  20. S. Y. Velásquez, L. F. García, G. Opelz, C. M. Alvarez, and C. Süsal, “Release of soluble CD30 after allogeneic stimulation is mediated by memory T cells and regulated by IFN-γ and IL-2,” Transplantation, vol. 96, no. 2, pp. 154–161, 2013. View at Publisher · View at Google Scholar · View at Scopus
  21. C. Süsal, J. Ovens, K. Mahmoud et al., “No association of kidney graft loss with human leukocyte antigen antibodies detected exclusively by sensitive Luminex single-antigen testing: a Collaborative Transplant Study report,” Transplantation, vol. 91, no. 8, pp. 883–887, 2011. View at Publisher · View at Google Scholar · View at Scopus
  22. L. E. Morales-Buenrostro, P. I. Terasaki, L. A. Marino-Vázquez, J. H. Lee, N. El-Awar, and J. Alberú, ““Natural” human leukocyte antigen antibodies found in nonalloimmunized healthy males,” Transplantation, vol. 86, no. 8, pp. 1111–1115, 2008. View at Publisher · View at Google Scholar · View at Scopus
  23. P. Gombos, G. Opelz, S. Scherer et al., “Influence of test technique on sensitization status of patients on the kidney transplant waiting list,” American Journal of Transplantation, vol. 13, no. 8, pp. 2075–2082, 2013. View at Publisher · View at Google Scholar · View at Scopus